Melanoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Melanoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 4 companies, in the next 180 days.
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaNCT06190951Pathological complete response (pCR) rate as assessed by Blinded Independent Pathological Review (BIPR) | Phase 2 | Active, not recruiting | 2026-11-02 | in 74 d | 2026-02-10 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT05973487Evaluate the safety of monotherapy and T- Plex combination TCR-Ts | Phase 1 | Active, not recruiting | 2026-12-30 | in 132 d | 2025-11-17 |
| CMPX | Compass Therapeutics | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-28 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| IDYA | IDEAYA Biosciences | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsNCT03947385Dose-limiting Toxicity (DLT) | Phase 1/2 | Recruiting | 2027-01-29 | in 162 d | 2026-06-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Melanoma
most recently updated first327 studies match. Showing the first 100 of 327 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsNCT06101134results2026-04-09Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose | Phase 2 | Active, not recruiting | Drug: relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20 | Melanoma | 100 | 2023-11-06 | 2025-04-10actual | — | 2026-08-19 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)NCT06246916Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on blinded independent central review (BICR) | Phase 3 | Recruiting | Drug: fianlimab, cemiplimab, relatlimab+nivolumab | Melanoma | 560 | 2024-09-09 | 2027-03-22 | in 214 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) | Phase 1/2 | Recruiting | Drug: AZD6750, rilvegostomig | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | 120 | 2025-07-29 | 2029-10-02 | in 1,139 d | 2026-08-19 |
| INCY | Incyte Corporation | $24.7B | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced MalignanciesNCT04370704results2026-08-17Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1/2 | Completed | Drug: INCAGN02385, INCAGN02390, INCMGA00012. | Melanoma | 61 | 2020-07-27 | 2025-08-25actual | — | 2026-08-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Phase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655Type, incidence and severity of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046033 | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | 2026-04-08 | 2028-07-14 | in 694 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: PF-07799544, PF-07799933 | Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer) | 124 | 2022-11-30 | 2027-08-02 | in 347 d | 2026-08-14 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNCT07459543Incidence of adverse events (AEs) | Phase 4 | Not yet recruiting | Drug: Nivolumab + Relatlimab | Unresectable Melanoma, Metastatic Melanoma | 40 | 2026-11-15 | 2029-05-26 | in 1,010 d | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| BMY | Bristol-Myers Squibb | $134.9B | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaNCT04099251results2023-07-27Recurrence Free Survival (RFS) | Phase 3 | Active, not recruiting | Biological: Nivolumab · Other: Placebo | Melanoma | 790 | 2019-10-28 | 2022-06-28actual | — | 2026-08-07 |
| NTRA | Natera, Inc. | $44.9B | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization. | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC, Melanoma (Skin Cancer), Melanoma (Skin) Stage IV, CRC, MSI High Colorectal Cancer, DMMR Colorectal Cancer, RCC, Renal Cell Cancer, RCC, Solid Tumors, Metastatic Solid Tumors, Advanced Solid Tumors, Advanced Solid Tumors Cancer | 920 | Dec 2026 | Dec 2033 | ≤ 2,690 d | 2026-08-04 |
| BMY | Bristol-Myers Squibb | $134.9B | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaNCT01024231results2021-03-22Number of Participants With an Adverse Event (AE) | Phase 1 | Completed | Drug: BMS-936558 (MDX1106-04), Ipilimumab | Malignant Melanoma | 127 | 2009-12-14 | 2014-02-04actual | — | 2026-08-03 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2) | Phase 1 | Recruiting | Drug: PF-07799933, binimetinib, midazolam, fluorouracil, leucovorin, oxaliplatin · Biological: cetuximab | Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1) | 267 | 2022-07-05 | 2028-04-23 | in 612 d | 2026-07-31 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursNCT06305247Phase 1: Percentage of participants with dose limiting toxicity (DLT) | Phase 1/2 | Active, not recruiting | Drug: IPN01194, IPN01194 | Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor | 36 | 2024-04-03 | 2028-03-20 | in 578 d | 2026-07-30 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab | Phase 1/2 | Recruiting | Drug: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer | 340 | 2019-12-10 | Jul 2033 | ≤ 2,537 d | 2026-07-29 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Drug: CTX-8371 | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma | 85 | 2024-03-19 | Dec 2026 | ≤ 133 d | 2026-07-28 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| REPL | Replimune, Inc. | $1.5B | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]NCT06264180Overall Survival (OS) | Phase 3 | Recruiting | Biological: Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab · Drug: Single-agent chemotherapy | Advanced Melanoma | 400 | 2024-07-11 | 2030-09-30 | in 1,502 d | 2026-07-15 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentNCT06848088Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613 | Phase 2 | Enrolling by invitation | Drug: Fianlimab+cemiplimab | Melanoma | 48 | 2025-04-14 | 2029-10-10 | in 1,147 d | 2026-07-13 |
| LLY | Eli Lilly and Company | $1.15T | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449results2026-07-09Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin | Phase 1 | Completed | Drug: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin | Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer | 353 | 2013-11-15 | 2019-02-19actual | — | 2026-07-09 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsNCT04609566Confirmed objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria | Phase 2 | Completed | Drug: brentuximab vedotin, pembrolizumab | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | 161 | 2021-01-26 | 2026-02-03actual | — | 2026-07-06 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryNCT05608291Relapse free survival (RSF) | Phase 3 | Active, not recruiting | Drug: Fianlimab, Cemiplimab, Pembrolizumab, Placebo | Melanoma | 1,564 | 2023-01-16 | 2026-07-27 | — | 2026-07-06 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsNCT05571839Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Drug: PF-08046049 | Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma | 41 | 2023-01-03 | 2026-06-01actual | — | 2026-07-01 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.NCT05727904Objective Response Rate and Progression Free Survival | Phase 3 | Recruiting | Biological: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period | Metastatic Melanoma, Unresectable Melanoma, Melanoma | 670 | 2023-03-30 | 2028-03-01 | in 559 d | 2026-06-26 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0 | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | 2019-04-26 | Jun 2026 | — | 2026-06-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaNCT04695977results2025-09-05Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) | Phase 2/3 | Terminatedsponsor's stated reason: Business Decision | Drug: CMP-001, Nivolumab | Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma | 20 | 2021-02-24 | 2024-07-22actual | — | 2026-06-15 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelNCT06940739Safety and Tolerability | Phase 1/2 | Recruiting | Biological: IOV-3001 | Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma | 42 | 2025-03-11 | Jun 2032 | ≤ 2,141 d | 2026-06-15 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerNCT05361174Phase I: Safety of IOV-4001 | Phase 1/2 | Recruiting | Biological: IOV-4001 | Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | 53 | 2022-07-20 | Sep 2027 | ≤ 406 d | 2026-06-11 |
| CATX | Perspective Therapeutics | $366M | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaNCT05655312Number of subjects with dose-limiting toxicities (DLTs) after the first administration of [212Pb]VMT01 as a monotherapy or in combination with nivolumab. | Phase 1/2 | Recruiting | Drug: [203Pb]VMT01, [212Pb]VMT01, Nivolumab | Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III | 300 | 2023-06-01 | 2027-12-31 | in 498 d | 2026-06-10 |
| IDYA | IDEAYA Biosciences | $3.7B | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsNCT03947385Dose-limiting Toxicity (DLT) | Phase 1/2 | Recruiting | Drug: IDE196, Binimetinib, Crizotinib | Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors | 336 | 2019-06-28 | 2027-01-29 | in 162 d | 2026-06-08 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaNCT05625399Time-averaged serum concentration over 28 days after the first dose (Cavgd28) of Nivolumab | Phase 3 | Active, not recruiting | Drug: Nivolumab + Relatlimab, rHuPH20 | Melanoma | 579 | 2023-03-06 | 2025-08-04actual | — | 2026-06-03 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been RemovedNCT03771859observationalRFS (relapse free survival) | — | Completed | — | Melanoma | 152 | 2019-01-16 | 2025-12-09actual | — | 2026-06-02 |
| AZN | AstraZeneca | — | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)NCT00600496Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies. | Phase 1 | Completed | Drug: AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus | Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer | 140 | 2007-12-14 | 2010-08-20actual | — | 2026-05-27 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928Objective Response Rate | Phase 2 | Terminatedsponsor's stated reason: After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints. | Biological: Lifileucel, LN-145, LN-145-S1 · Drug: Pembrolizumab, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed | Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer | 225 | 2019-05-07 | 2026-02-20actual | — | 2026-05-15 |
| AGEN | Agenus Inc. | $339M | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalNCT06751524expanded access | — | Available | Drug: Botensilimab, Balstililmab | Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC), Melanoma, Sarcoma, Ovarian Cancer, Prostate Cancer | — | — | — | — | 2026-05-15 |
| EIKN | Eikon Therapeutics | $567M | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.NCT06697301Progression Free Survival (PFS) | Phase 2/3 | Recruiting | Drug: EIK1001, Pembrolizumab (KEYTRUDA® ) | Advanced Melanoma | 740 | 2025-05-22 | Dec 2035 | ≤ 3,420 d | 2026-05-08 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487Part A and Part B: Number of participants with dose limiting toxicities (DLTs) in dose escalation | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns | Drug: PF-08046032, Sasanlimab | Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer | 6 | 2025-05-08 | 2026-04-23actual | — | 2026-05-08 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their BodyNCT06413680Incidence of Dose-Limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: REGN10597, Cemiplimab | Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors | 240 | 2024-09-23 | 2030-02-03 | in 1,263 d | 2026-04-28 |
| PFE | Pfizer | $155.3B | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesNCT06974734Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns | Drug: PF-08046037, sasanlimab | Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | 8 | 2025-05-06 | 2026-03-20actual | — | 2026-04-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaNCT05352672Progression-free survival (PFS) | Phase 3 | Active, not recruiting | Drug: Fianlimab, Cemiplimab, Pembrolizumab, Placebo | Melanoma | 1,546 | 2022-07-14 | 2026-03-12actual | — | 2026-04-22 |
| INCY | Incyte Corporation | $24.7B | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaNCT01604889Phase 1: Number of patients with adverse events as a measure of Safety and Tolerability. | Phase 1/2 | Terminatedsponsor's stated reason: Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued. | Drug: Epacadostat, ipilimumab | Melanoma | 50 | 2012-03-29 | 2016-12-27actual | — | 2026-04-21 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | Expanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseNCT05398640expanded access | — | Available | Biological: OOS AMTAGVI | Unresectable Melanoma, Metastatic Melanoma | — | — | — | — | 2026-04-20 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaNCT07288203Objective Response Rate | Phase 2 | Active, not recruiting | Biological: Lifileucel | Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma | 100 | 2025-11-28 | Dec 2032 | ≤ 2,325 d | 2026-04-20 |
| CMPX | Compass Therapeutics | $430M | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesNCT03881488Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities | Phase 1 | Completed | Drug: CTX-471, Pembrolizumab (KEYTRUDA®) | Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer | 100 | 2019-05-17 | 2025-05-21actual | — | 2026-04-17 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Patients With Advanced Solid TumorsNCT05423262Number of participants with dose-limiting toxicities (DLTs) (Part 1 and 2) | Phase 1/2 | Recruiting | Biological: TRK-950, TRK-950, TRK-950, TRK-950 · Drug: Nivolumab | Solid Tumor, Melanoma | 49 | 2022-07-06 | Dec 2027 | ≤ 498 d | 2026-04-13 |
| PFE | Pfizer | $155.3B | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaNCT04657991Safety Lead In (SLI): Incidence of Dose Limiting Toxicities (DLTs) | Phase 3 | Active, not recruiting | Drug: Encorafenib, Binimetinib, Pembrolizumab | Melanoma | 257 | 2021-01-15 | 2026-01-12actual | — | 2026-04-07 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsNCT06566092Incidence rate of Treatment-Emergent Adverse Events | Phase 1 | Active, not recruiting | Biological: LN-145/LN-144 | Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma, Ewing Sarcoma | 40 | 2024-03-28 | Jul 2026 | — | 2026-04-06 |
| AMGN | Amgen | $229.9B | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaNCT05907122Area Under the Serum Concentration-time Curve from Time Zero to 28 Days (AUC0-28d) | Phase 3 | Completed | Drug: ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab | Melanoma | 256 | 2023-07-26 | 2025-03-26actual | — | 2026-03-27 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaNCT02360579results2025-12-09Disease Assessment for Objective Response Rate | Phase 2 | Completed | Biological: Lifileucel | Metastatic Melanoma | 220 | 2015-09-24 | 2024-10-24actual | — | 2026-03-25 |
| PFE | Pfizer | $155.3B | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerNCT06580938Number of Participants With Dose-Limiting Toxicity (DLT) (Parts 1 and 2) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Biological: PF-07921585, Sasanlimab | Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer | 4 | 2024-11-11 | 2025-07-14actual | — | 2026-03-23 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid TumorsNCT06799533Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns. | Drug: PF-08046031 | Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors | 11 | 2025-05-01 | 2026-02-23actual | — | 2026-03-18 |
| BNTX | BioNTech SE | — | Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced MelanomaNCT02410733Number of Adverse Events as a Measure of safety and tolerability | Phase 1 | Completed | Biological: Lipo-MERIT | Melanoma | 119 | Mar 2015 | 2023-06-20actual | — | 2026-03-12 |
| PFE | Pfizer | $155.3B | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaNCT05926960Objective Response Rate (ORR) is defined as the proportion of participants in each treatment arm with a confirmed best overall response of either Complete Response (CR) or Partial Response (PR), as determined by investigator assessment per RECIST v1.1 | Phase 2 | Terminatedsponsor's stated reason: Study terminated due to inability to recruit the target number of patients. There were no safety and/or efficacy concerns involved in the decision to stop enrollment. | Drug: encorafenib, binimetinib, pembrolizumab, ipilimumab, nivolumab | Melanoma | 38 | 2023-06-13 | 2026-02-02actual | — | 2026-03-09 |
| PFE | Pfizer | $155.3B | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaNCT01909453results2021-07-12Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib Group | Phase 3 | Completed | Drug: LGX818, MEK162, vemurafenib | Melanoma | 921 | 2013-09-12 | 2016-11-09actual | — | 2026-02-27 |
| IMCR | Immunocore Ltd | $1.9B | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)NCT05549297Overall Survival (OS) | Phase 3 | Recruiting | Drug: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice | Advanced Melanoma | 540 | 2022-12-19 | Mar 2028 | ≤ 589 d | 2026-02-25 |
| IMCR | Immunocore Ltd | $1.9B | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)NCT06112314Progression-Free Survival (PFS) | Phase 3 | Recruiting | Drug: Brenetafusp, Nivolumab, Nivolumab + Relatlimab | Advanced Melanoma | 680 | 2024-06-05 | 2027-10-16 | in 422 d | 2026-02-25 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersNCT03400332results2025-06-19Number of Participants Experiencing Adverse Events (AEs) - Part 1 | Phase 1/2 | Completed | Drug: BMS-986253 · Biological: Nivolumab, Ipilimumab · Other: Placebo | Cancer, Melanoma | 281 | 2018-02-12 | 2024-04-26actual | — | 2026-02-24 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962Time Activity Curves (TACs) | Early Phase 1 | Recruiting | Drug: 177Lu-RAD204 | PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer, Cutaneous Melanoma, HNSCC, Endometrial Cancer, Mmr Deficiency, MSI-High | 30 | 2024-06-03 | Dec 2027 | ≤ 498 d | 2026-02-19 |
| REPL | Replimune, Inc. | $1.5B | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348Percentage of adverse events (AEs) | Phase 2 | Active, not recruiting | Biological: RP1, nivolumab | Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma | 340 | 2017-09-20 | Jun 2028 | ≤ 680 d | 2026-02-13 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaNCT06190951Pathological complete response (pCR) rate as assessed by Blinded Independent Pathological Review (BIPR) | Phase 2 | Active, not recruiting | Drug: cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo | Melanoma | 151 | 2024-09-18 | 2026-11-02 | in 74 d | 2026-02-10 |
| MGNX | MacroGenics | $261M | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117results2026-02-09Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator | Phase 2 | Terminatedsponsor's stated reason: Business reasons | Biological: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine · Drug: Abiraterone, Enzalutamide | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma | 192 | 2023-06-13 | 2024-07-04actual | — | 2026-02-09 |
| AMGN | Amgen | $229.9B | Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic InfectionNCT02910557observationalIncidence Rate | — | Completed | — | Melanoma, Herpetic Infection | 187 | 2017-08-10 | 2026-01-30actual | — | 2026-02-05 |
| SNY | Sanofi | — | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)NCT04913220results2026-02-04All Cohorts: Objective Response Rate (ORR) | Phase 1/2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Drug: THOR-707, Cemiplimab | Malignant Melanoma, Squamous Cell Carcinoma of Skin | 46 | 2021-07-15 | 2023-08-22actual | — | 2026-02-04 |
| AGEN | Agenus Inc. | $339M | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaNCT05529316Objective Response Rate | Phase 2 | Active, not recruiting | Drug: Botensilimab, Balstilimab | Advanced Melanoma | 150 | 2022-12-12 | Feb 2028 | ≤ 558 d | 2026-01-16 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | 2025-07-21 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2018-12-11 | 2029-08-31 | in 1,107 d | 2026-01-14 |
| 4568.T | Daiichi Sankyo Co., Ltd. | $31.7B | A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated MelanomaNCT02975700results2020-04-09Summary of Best Overall Response Following Twice Daily Administration of PL3397 at 1000 mg/Day In Participants With Unresectable or Advanced KIT-mutated Melanoma | Not applicable | Completed | Drug: PLX3397 | Melanoma | 6 | 2017-01-31 | 2018-08-31actual | — | 2026-01-13 |
| AMGN | Amgen | $229.9B | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaNCT06054555Objective response by Week 49 | Phase 3 | Active, not recruiting | Drug: ABP 206, Nivolumab | Melanoma | 633 | 2023-11-02 | 2028-01-25 | in 523 d | 2026-01-12 |
| REPL | Replimune, Inc. | $1.5B | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3NCT06887348observationalEvaluate the long-term safety of patients treated with an RPx product | — | Recruiting | Other: Observational study with no interventions | Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma | 50 | 2025-12-12 | Dec 2030 | ≤ 1,594 d | 2026-01-12 |
| BNTX | BioNTech SE | — | A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of TreatmentNCT04526899results2025-12-15Arm 1: Objective Response Rate (ORR) | Phase 2 | Completed | Biological: BNT111, Cemiplimab | Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma | 184 | 2021-05-19 | 2024-01-25actual | — | 2026-01-08 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaNCT05002569results2026-01-08Recurrence Free Survival (RFS) | Phase 3 | Terminatedsponsor's stated reason: Inability to meet protocol objectives | Biological: Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination | Melanoma | 1,093 | 2021-10-19 | 2024-12-16actual | — | 2026-01-08 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Compassionate Use of VidutolimodNCT06063746expanded access | — | No longer available | Drug: Vidutolimod | Refractory Melanoma | — | — | — | — | 2026-01-08 |
| CTMX | CytomX Therapeutics | $739M | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsNCT03993379results2021-12-01Overall Response Rate by RECIST v 1.1 | Phase 2 | Terminatedsponsor's stated reason: Sponsor's Decision | Drug: CX-072, Ipilimumab | Solid Tumor, Unresectable or Metastatic Melanoma | 3 | 2019-11-20 | 2020-05-21actual | — | 2025-12-26 |
| REPL | Replimune, Inc. | $1.5B | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced MelanomaNCT06590480expanded access | — | No longer available | Biological: RP1, Nivolumab | Advanced Melanoma | — | — | — | — | 2025-12-18 |
| MRNA | ModernaTX, Inc. | $25.1B | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)NCT03897881Recurrence-Free Survival (RFS), Assessed Using Radiological Imaging | Phase 2 | Active, not recruiting | Drug: mRNA-4157 · Biological: Pembrolizumab | Melanoma | 267 | 2019-07-18 | 2032-11-30 | in 2,294 d | 2025-12-03 |
| 051910.KS | LG Chem | $13.7B | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCNCT06332755Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC | Phase 1 | Recruiting | Drug: Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab | Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma | 76 | 2024-06-05 | Nov 2027 | ≤ 467 d | 2025-11-24 |
| TNG.PA | Transgene | $231M | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsNCT04725331Phase I: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision following completion of Phase I part not driven by safety reason | Biological: BT-001 · Drug: Pembrolizumab [KEYTRUDA®] | Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Small Cell Lung Cancer | 31 | 2021-02-25 | 2025-10-22actual | — | 2025-11-21 |
| CCCC | C4 Therapeutics, Inc. | $514M | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsNCT05668585Frequency and severity of AEs and SAEs | Phase 1 | Completed | Drug: CFT1946, Trametinib, Cetuximab | Solid Tumors, Melanoma, NSCLC, CRC, ATC | 89 | 2022-12-08 | 2025-11-05actual | — | 2025-11-21 |
| BMY | Bristol-Myers Squibb | $134.9B | A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)NCT04196452observationalFrequency of Adverse Events (AEs) Grades 3-4 | — | Active, not recruiting | Drug: Ipilimumab | Melanoma | 10 | 2019-08-12 | 2034-02-20 | in 2,741 d | 2025-11-20 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT05973487Evaluate the safety of monotherapy and T- Plex combination TCR-Ts | Phase 1 | Active, not recruiting | Biological: TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201 | Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma | 840 | 2024-05-06 | 2026-12-30 | in 132 d | 2025-11-17 |
| BOLT | Bolt Biotherapeutics, Inc. | $6M | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesNCT06052852Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to CTCAE v5.0 | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BDC-3042, Cemiplimab | Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma | 17 | 2023-10-11 | 2025-08-01actual | — | 2025-11-17 |
| BMY | Bristol-Myers Squibb | $134.9B | Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabNCT07091695observationalParticipant baseline demographics | — | Completed | Biological: Nivolumab + relatlimab, Nivolumab + ipilimumab | Melanoma | 100 | 2025-05-11 | 2025-11-06actual | — | 2025-11-12 |
| TCRT | Alaunos Therapeutics | $5M | Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat MelanomaNCT01397708results2025-10-29Number of Participants With Treatment-Emergent Adverse Events | Phase 1/2 | Completed | Biological: INXN-2001 · Drug: INXN-1001 | Melanoma | 26 | Aug 2011 | Sep 2014actual | — | 2025-10-29 |
| TEM | Tempus AI | $8.6B | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437results2025-10-29Overall Response Rate (ORR) - Independent Central Review (ICR) | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges | Drug: Niraparib | Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer | 22 | 2022-03-15 | 2024-08-06actual | — | 2025-10-29 |
| 4523.T | Eisai Inc. | $8.7B | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsNCT05091346results2025-10-24Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs) | Phase 1/2 | Completed | Drug: E7386, Pembrolizumab, Lenvatinib | Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms | 89 | 2021-10-27 | 2024-10-15actual | — | 2025-10-24 |
| PFE | Pfizer | $155.3B | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementNCT04543188results2025-10-23Number of Participants With Dose Limiting Toxicities (DLTs): Phase 1a | Phase 1 | Terminatedsponsor's stated reason: Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities. | Drug: PF-07284890, Binimetinib, Midazolam | Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms | 65 | 2021-01-08 | 2024-03-20actual | — | 2025-10-23 |
| MGNX | MacroGenics | $261M | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496Number of participants with adverse events (AEs) | Phase 1 | Completed | Biological: vobramitamab duocarmazine, lorigerlimab | Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma | 31 | 2022-04-19 | 2025-06-24actual | — | 2025-10-14 |
| PFE | Pfizer | $155.3B | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsNCT06285097Number of patients with dose limiting toxicities (DLTs) in dose escalation (Part 1A and Part 1B) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns. | Drug: PF-07820435 · Biological: Sasanlimab | Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 9 | 2024-02-08 | 2025-01-03actual | — | 2025-09-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaNCT03470922results2022-03-29Progression Free Survival (PFS) | Phase 2/3 | Active, not recruiting | Biological: Relatlimab, Nivolumab | Melanoma | 714 | 2018-04-11 | 2021-01-25actual | — | 2025-09-09 |
| IMRX | Immuneering Corporation | $221M | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsNCT05585320Phase 1: Adverse Events | Phase 1/2 | Active, not recruiting | Drug: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E) | Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC) | 209 | 2022-10-31 | Jun 2026 | — | 2025-09-02 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2021-03-19 | 2025-08-25actual | — | 2025-08-28 |
| INCY | Incyte Corporation | $24.7B | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)NCT02752074results2019-05-15Progression-free Survival | Phase 3 | Completed | Drug: pembrolizumab + epacadostat, pembrolizumab + placebo | Melanoma | 706 | 2016-06-21 | 2018-01-08actual | — | 2025-08-24 |
| GH | Guardant Health, Inc. | $21.5B | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444observationalDistant Recurrence Free Interval (D-RFi) | — | Recruiting | Diagnostic test: Guardant Reveal | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 2,020 | 2021-09-07 | Aug 2029 | ≤ 1,107 d | 2025-08-22 |
| INCY | Incyte Corporation | $24.7B | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)NCT02327078results2023-04-26Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1/2 | Completed | Drug: Nivolumab, Epacadostat, Chemotherapy | B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma | 307 | 2014-11-26 | 2020-06-16actual | — | 2025-08-14 |
| MGNX | MacroGenics | $261M | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerNCT02475213results2025-08-11Number of Participants With Dose-limiting Toxicities (DLT) After Administration of Enoblituzumab and Pembrolizumab or Retifanlimab | Phase 1 | Completed | Biological: Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab | Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma | 146 | Jul 2015 | 2021-08-18actual | — | 2025-08-11 |
| AAPG | Ascentage Pharma Group Inc. | — | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsNCT03611868Maximum Tolerated Dose | Phase 1/2 | Active, not recruiting | Drug: Phase 1b: APG-115+pembrolizumab | Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST) | 230 | 2018-08-29 | 2025-12-30 | — | 2025-08-07 |
| MGNX | MacroGenics | $261M | MGC018 With or Without MGA012 in Advanced Solid TumorsNCT03729596results2025-07-31Number of Patients With Adverse Events of Vobramitamab Duocarmazine as Assessed by CTCAE v4.03 | Phase 1/2 | Terminatedsponsor's stated reason: Business decision | Biological: vobramitamab duocarmazine | Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer | 143 | 2018-11-21 | 2023-03-18actual | — | 2025-07-31 |
| AZN | AstraZeneca | — | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionNCT05061134results2025-05-21Main Study: Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: Ceralasertib · Biological: Durvalumab | Melanoma | 194 | 2022-08-11 | 2024-04-12actual | — | 2025-07-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Melanoma is matched — 21 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Melanoma
- Malignant Melanoma
- Metastatic Melanoma
- Advanced Melanoma
- Cutaneous Melanoma
- Unresectable Melanoma
- Melanoma (Skin)
- Melanoma Stage IV
- Stage IV Melanoma
- Melanoma Stage III
- Stage III Melanoma
- Unresectable or Metastatic Melanoma
- Advanced Cutaneous Melanoma
- Advanced or Metastatic Melanoma
- Cutaneous Melanoma, Stage III
- Cutaneous Melanoma, Stage IV
- Malignant Melanoma (Cutaneous)
- Melanoma (Skin Cancer)
- Mucosal Melanoma
- Refractory Melanoma
- Unresected Stage IIIb to IVM1c Melanoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Melanoma” (a text search, wider than this page)